Table 2: Observational Studies of the Association of Preprocedural ANP or NT-proANP Levels and AF Recurrences Following Successful ECV.
| Study Characteristics | AF Duration | n | AF Recurrence Rate | Follow-up Period | ANP in SR Group | SR Group n | ANP in AF Group | ||
|---|---|---|---|---|---|---|---|---|---|
| ANP | |||||||||
| van den Berg et al. 1995 | CHF, NYHA II or III | 20 months median | 18 | 9/18 | 6 weeks | 63 ± 50 pmol/L | 70 ± 48 pmol/L | 9 | |
| Theodorakis et al. 1996 | Non-valvular AF, NYHA I or II | 6 ± 5 months (2-13 months) | 19 | 11/19 | 3 months | 129 ± 58 fmol/mL | 8 | 112 ± 58 fmol/mL | 11 |
| Mabuchi et al. 2000 | CHF, NYHA II or III | 20.4 months | 65 | 29/65 | 2 months | 67.4 ± 10.0 pg/rnL | 36 | 65.8 ± 12.3 pg/mL | 29 |
| Wozakowska et al. 2004 | Broad spectrum of underlying disease, NYHA I, II or III | 7.1 ± 7.1 months | 35 | 6/35 | 1 month | 58.1 ± 13.0 pg/mL | 29 | 60.2 ±11.2 pg/mL | 6 |
| Thomas et al. 2005 | NYHA I or II | >1 month and <1 year | 23 | 9/23 | 1 month | 150 ± 34 pg/mL | 14 | 250 ± 62 pg/mL | 9 |
| NT-proANP | |||||||||
| Kim et al. 2009 | Broad spectrum of underlying disease | >1 month | 74 | 48/74 | 13.2 ± 11.0 months | 6.68 ± 4.09 nmol/L | 26 | 4.92 ± 4.36 nmol/L | 48 |
| Bartkowiak et al. 2010 | Preserved LV systolic function | 12.3 ± 15.3 weeks | 43 | 19/43 | 1 month | 5.1 ± 3.5 nmol/L | 24 | 4.4 ± 2.0 nmol/L | 19 |
| Govindan et al. 2012 | Non-valvular AF, preserved LV systolic function | <18 months | 54 | 33/54 | 12 month | 5.9 ± 2.4 nmol/L | 21 | 7.3 ± 1.9 nmol/L | 33 |
AF = atrial fibrillation; ANP = atrial natriuretic peptide; CHF = congestive heart failure; LV = left ventricular; NT-proBNP = N-terminal portion of proBNP; SR = sinus rhythm.